At Stock Options Channel, our YieldBoost formula has looked up and down the IDIX options chain for the new October 18th contracts and identified one put and one call contract of particular interest. The put contract at the $6.00 strike …
Idenix Pharmaceuticals (IDIX): IDIX stock is up 3.9% today and up 30.8% in the ... Article printed from InvestorPlace Media, http://investorplace.com/2014/05/biggest-movers-in-healthcare-stocks-now-isis-cldx-hznp-idix-isis-cldx-hznp/.
Is Idenix Pharmaceuticals Inc (NASDAQ:IDIX) an excellent stock to buy now? Investors who are in the know are taking a bearish view. The number of bullish hedge fund positions dropped by 6 in recent months. At the moment, there are …
Collecting that bid as the premium represents a 7.5% return against the $4 commitment, or a 19.4% annualized rate of return (at Stock Options Channel we call this the YieldBoost). Selling a put does not give an investor access to IDIX’s …
Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) was the biggest gainer of all listed stocks on ... By many counts this is also close to a penny stock because its share price is under $5.00. Idenix is far from being without risk and would still …
To read the entire report visit: http://www.stockpreacher.com/n/IDIX See what investors are saying about IDIX at penny stock forum StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com …
As a result, our Buy call on IDIX stock, which was largely based on the asymmetric upside potential of wholly-owned nucleotide analogues (nucs) for treatment of Hepatitis C (HCV), has played out. Given media reports that other parties …
Fulton Financial Corp (FULT): Credit Suisse cuts the company to Underperform from Neutral. Idenix Pharmaceuticals Inc (IDIX): The stock is now Underperform from Neutral at Robert W. Baird, which says that the Food and Drug …
Today’s daily gainers are Idenix Pharmaceuticals Inc (NASDAQ:IDIX), LinnCo ... Fridays for CVR Refining LP (NYSE:CVRR). The firm’s stock price fell to $21.68, a -10.93% loss. This is likely the result of reported poor Q3 profits. …
The costs of bringing ACH-3422 through the FDA trials, and the risk of it being ineffective, suggest the stock shouldn't be currently trading for more than $5 per share. Ever since ACHN started to rally out of sympathy for the Idenix (IDIX) …